‘Thrombin Responsive Nanoparticles for Prophylaxis and Treatment of Acute Thrombosis’
Monash University, VIC
Co-funded by Rotary District 9830
“Currently available treatments for thrombosis are associated with debilitating clinical side-effects, they can only be given in the hospital and not in the ambulance. ”
My name is Jason Palazzolo. I was born, raised and currently live in Melbourne, Victoria. I have graduated with a Bachelor of Science and a Master of Biomedical Science, both from the University of Melbourne. Following my university studies, I have since pursued a career in the pharmaceutical industry, where I have held several different positions, such as a vaccine manufacturer and clinical trial project co-ordinator. Most recently, I worked as a research and development scientist at Seqirus (a CSL company).
In regards to my personal life, I am currently planning my wedding with my wife-to-be, which is scheduled for early 2019. Also, I’m a passionate follower of the Australian Football League of which I am a long-term member and supporter of the North Melbourne Kangaroos Football Club. By undertaking this PhD, I hope to improve the health and wellbeing of patients diagnosed with thrombosis, across Australia and worldwide. I am grateful to be awarded my PhD scholarship from Australian Rotary Health and Rotary District 9830 and I look forward to working closely with both groups going forward.
This study aims to discover a novel therapy for the prevention and treatment of thrombosis. The research aims of this project are listed below:
- To develop a novel therapy that offers improved clinical outcomes when compared against currently available therapies.
- Improved clinical outcomes refer to; (i) offering an enhanced ability to breakdown thrombotic blood clots and (ii) significantly reducing or entirely removing the severe side-effects commonly associate with currently available therapies.
- To adopt and demonstrate innovative biomedical scientific techniques.
- We aim to combine two new and exciting fields of biomedical research being (i) nanoparticles as a drug delivery platform and (ii) single-chain antibody technologies.
- To improve upon the existing academic knowledge of thrombosis-related CVD.
- In order to address previously unanswered scientific questions relating to thrombosis.
Furthermore, any encouraging laboratory findings may be translated to clinical trials. If these clinical trials are successful, this novel therapy will most likely be made clinically available to all patients suffering from CVD, specifically thrombosis, which will improve their disease prognosis.
Therefore, this project aims to offer Australian and worldwide patients suffering from thrombosis an improved quality of life and significantly reduced burden of disease. This exciting prospect is only made possible through the potential discovery of a promising and novel therapy, particularly one that encompasses innovative frontiers of biomedical science.
Supervisors: Associate Professor Christoph Hagemeyer